Spero Therapeutics, Inc. (SPRO)
SPRONASDAQ-GSBiotechnology: Pharmaceutical Preparations
$0.9300
-0.0863 (-8.49%) today
Closed, Nov 16, 4:00 PM ET
- Market cap
- $58.26m
- P/E
- 11.6
- EPS, last 4 quarters
- $0.0800
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9521 to $3.08
- Average volume
- –
- Previous close
- $1.02
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $6.00, +545.2% from here
Earnings
next estimate $-0.1400Next report
Dec 2025
–
Mar 2026
–
Jun 2026
–
Sep 2026
-14.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $41.30m | $258.0k | – | – |
| Gross profit | $41.30m | $258.0k | – | – |
| Operating income | $31.41m | -$7.54m | -$9.93m | -$41.91m |
| Net income | $31.52m | -$7.20m | -$9.55m | -$44.28m |
News
8 latest- Cantor Fitzgerald Initiates Coverage of Spero Therapeutics at OverweightFintel · Oct 28, 2026
- Spero Therapeutics, Inc. Announces Retirement of Chief Operating Officer Timothy KeutzerFintel · Oct 27, 2026
- Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related DiseaseMarketBeat · Oct 21, 2026
- Spero Therapeutics Consensus Price Target Raised 25% to $5.10Fintel · Oct 1, 2026
- Spero Therapeutics (SPRO) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 19, 2026
- Spero Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 12, 2026
- Spero Therapeutics Names Debra Jeske Zack As Chief Medical Officer RTTNews · Jul 27, 2026
- Innovent Grants Spero Ex-China Rights To Anti-CD40L Antibody IBI355 In Up To $1.1 Bln Deal RTTNews · Jul 14, 2026
The company
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company's lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immune-mediated diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- sperotherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.